

28 January 2015

MSD

Merck Sharp & Dohme (New Zealand) Limited
Level 3 109 Carlton Gore Road
Newmarket, Auckland 1023
PO Box 99-851 Newmarket Auckland 1149
T 09 523-6000
F 09 523-6001
msd.co.nz



**UPDATE: Notice of cessation of manufacture, distribution and supply of
TOLVON (mianserin)**

Dear Healthcare Professional:

Following our letter of March 2014, this letter is to update you on our progress towards the discontinuation of TOLVON (mianserin).

Due to falling demand our supplies of TOLVON in New Zealand are now anticipated to last beyond our previously stated estimate. Assuming that demand continues to fall as patients are transitioned to alternative treatments we expect that we will continue to hold stock throughout most of 2015. The expiry date of the remaining product held in New Zealand is such that we will cease distribution in November 2015. We strongly encourage you to ensure all patients are transitioned well before this date.

As mentioned in our previous communication, there is no impact to the quality or safety of TOLVON currently on the market and in use by patients. We advise however, that you begin discussing and/or transitioning your patients to an appropriate alternative therapy as soon as possible. MSD is unable to provide comment on individual patient circumstances and recommends that if you have any questions or concerns about the appropriate treatment to transition your patient(s) to you should discuss these with a depression specialist.

We apologise for any difficulty this may cause you and your patients.

Please contact MSD Customer Services on 0800 500 673 for any further questions.

A handwritten signature in blue ink, appearing to read "M. Hartevelt", is written over a light blue rectangular background.

Michael Hartevelt
Market Access Manager
MSDNZ